Prime Medicine received FDA IND approval for PM-647, an investigational in vivo Prime Editor program targeting α-1 antitrypsin deficiency (AATD). The first-in-human phase I/II trial is expected to evaluate a one-time intravenous infusion in adults, including patients with both lung and liver manifestations. For gene editing companies and rare-disease developers, this is a concrete regulatory milestone that demonstrates progress from platform design into human evaluation. The IV route and one-time dosing concept also reflect how developers aim to simplify long-term burden for AATD patients. The industry impact is twofold: it adds another Prime Editor candidate to the clinical landscape and it provides an additional reference point for regulators’ comfort with editing approaches in systemic indications beyond single-organ constraints.